BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

Serial circulating tumor DNA analysis can demonstrate rapid clonal dynamics that evolve during response and resistance to both standard chemotherapy and targeted therapy of BRAF-mutant colon cancer ...

(RTTNews) - Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI (encorafenib) in combination with ...

Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...

Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this ...

Figure 1: Chest MRI 04/22/2021. Soft tissue tumor (32 × 23 mm) on the right chest wall, located deep to the superficial fascia, in relation to the serratus muscle and extending towards the intercostal ...

Survivorship Care for People Affected by Advanced or Metastatic Cancer: Building on the Recent Multinational Association of Supportive Care in Cancer-ASCO Standards and Practice Recommendations The ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...